Algorae Pharmaceuticals Limited (LVCLF)

Market Cap	7.53M
Revenue (ttm)	77.48K
Net Income (ttm)	-802.77K
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	175,000
Average Volume	17,575
Open	0.0064
Previous Close	0.0064
Day's Range	0.0064 - 0.0064
52-Week Range	0.0004 - 0.0103
Beta	0.12
RSI	66.40
Earnings Date	Apr 23, 2025

About Algorae Pharmaceuticals

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company’s product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer’s disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 48
• Stock Exchange: OTCMKTS
• Ticker Symbol: LVCLF

Financial Performance

In 2024, Algorae Pharmaceuticals's revenue was 125,200, an increase of 197.98% compared to the previous year's 42,016. Losses were -2.10 million, -0.57% less than in 2023.

Financial numbers in AUD